Subscription Models for High-Value, High-Cost Medicines: Lessons Learned from the US Experience

Government healthcare payors in Asia and globally may face financial incentives to restrict use of high-cost medications. Yet, restrictions on access to high-value medications may have deleterious effects on population health. Advance purchase commitments (APCs), wherein a payor commits to purchase a certain quantity of medications at lower prices, offer payors incentives to increase access to high-value medications and companies guaranteed revenue; a potential win-win-win for patients, business and society.

Dr. Conti will discuss the United States payor experience with subscription models, a type of APC, to support increased access to high-value medicines. She will focus on direct acting antivirals (DAAs), available since 2013, that can cure chronic infection with Hepatitis C virus (HCV). With prices upwards of $90,000 for a treatment course, many payors struggle to ensure access to DAAs to populations in need of treatment. Since 2018, several US states have implemented HCV subscription models and a national HCV elimination strategy featuring a DAA subscription model has been announced.

Dr. Conti will review the empirical evidence on impacts and lessons learned from implementation to date, as well as provide a framework for payors interested in pursuing subscription models targeting DAAs and other high-value, high-cost medicines.

Speaker: Rena Conti, Boston University

Register at weblink

Room: Philippines Conference Room, Third Floor, Central, C330